|
Jun 28
|
Lantheus Joins FIBRE Consortium with Pfizer, Lumina to Revolutionize Fibrotic Disease Treatment
|
|
Jun 27
|
PFE's Hympavzi Phase III Hemophilia Study With Inhibitors Meets Goal
|
|
Jun 27
|
Pfizer reports positive results from Phase III BAISIS trial for haemophilia
|
|
Jun 27
|
Sickle Cell Disease Treatment Market Analysis and Forecast, 2025-2035 | Intensifying Competition as Key Players Advance Gene and Novel Therapies
|
|
Jun 26
|
Pfizer (NYSE:PFE) Announces Positive Results For Hemophilia Treatment And Declares $0.43 Dividend
|
|
Jun 26
|
All You Need to Know About Pfizer (PFE) Rating Upgrade to Buy
|
|
Jun 26
|
Smartly’s Flagship Event ADVANCE Returns: New Voices, Big Ideas, and the Future of Marketing
|
|
Jun 26
|
Innovation in Focus: Highlights from the Two-Day London Biotechnology Show 2025
|
|
Jun 26
|
Pfizer Announces Positive Topline Phase 3 Results for HYMPAVZI™ in Hemophilia A or B with Inhibitors
|
|
Jun 25
|
Pfizer Declares Third-Quarter 2025 Dividend
|
|
Jun 25
|
Will New Drugs Enable BMY to Offset the Impact of Generic Competition?
|
|
Jun 25
|
Pfizer Invites Public to View and Listen to Webcast of August 5 Conference Call with Analysts
|
|
Jun 25
|
Arbor Biotechnologies Appoints Mikael Dolsten, M.D., Ph.D., to Board of Directors
|
|
Jun 25
|
Does Pfizer (NYSE:PFE) Have A Healthy Balance Sheet?
|
|
Jun 25
|
3 Reasons PFE is Risky and 1 Stock to Buy Instead
|
|
Jun 24
|
Pfizer to Face Several Headwinds: Can It Successfully Navigate Them?
|
|
Jun 24
|
Will AbbVie's Growing Oncology Portfolio Aid Top-line Growth?
|
|
Jun 24
|
My 5 Favorite Dirt Cheap Stocks to Buy Right Now
|
|
Jun 24
|
Kinase Inhibitors in Autoimmune Diseases Research Report 2025-2035 | Market Accelerates Amid Rising Disease Prevalence, Kinase Innovation, and Demand for Safer Treatments
|
|
Jun 15
|
Pfizer Inc. (NYSE:PFE) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?
|